Yiyun Zhang

发表

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

K. Davis, S. Rives, Krysta D Schlis, 2018, The New England journal of medicine.

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

D. Pennell, A. Piga, Yiyun Zhang, 2014, Blood.

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two‐year results including pharmacokinetics and concomitant hydroxyurea

E. Vichinsky, Yiyun Zhang, B. Files, 2013, American journal of hematology.

Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis

K. Davis, S. Rives, Krysta D Schlis, 2017 .

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

D. Pennell, A. Piga, Yiyun Zhang, 2012 .

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

R. Chawla, M. Perales, S. Nikiforow, 2019, Blood.

A proteogenomic signature of age-related macular degeneration in blood

J. Lamb, V. Gudnason, V. Emilsson, 2021, Nature Communications.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis

P. Malfertheiner, H. Bonkovsky, P. Brissot, 2010, Hepatology.

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

R. Chawla, S. Grupp, S. Nikiforow, 2019, Blood.

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

P. Brissot, M. Cappellini, Y. Deugnier, 2011, Gastroenterology.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

G. Lucchini, P. Veys, F. Farzaneh, 2021, Nature Medicine.

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

S. Rives, Krysta D Schlis, A. Baruchel, 2016 .

187 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS

P. Malfertheiner, H. Bonkovsky, P. Brissot, 2009 .

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study

V. Viprakasit, R. Galanello, A. Taher, 2012 .

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

M. Cappellini, V. Viprakasit, R. Galanello, 2011 .

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

E. Tholouli, K. Ardeshna, K. Peggs, 2023, Blood.